Chazal, Etienne
Morin, Lucas
Chocron, Sidney
Lassalle, Philippe
Pili-Floury, Sebastien
Salomon du Mont, Lucie
Ferreira, David
Samain, Emmanuel
Perrotti, Andrea
Besch, Guillaume
Article History
Received: 6 June 2023
Accepted: 12 August 2023
First Online: 24 August 2023
Declarations
:
: The authors declare no competing interests.
: The ENDOLUNG study was approved by the Institutional Review Board (CPP EST II, registered under the number 10/544) and was registered on clinicaltrials.gov (NCT02542423). All patients provided written informed consent.
: Not applicable.